Browse by UCL people
Group by: Type | Date
Number of items: 157.
Article
Alberro, JA;
Ballester, B;
Deulofeu, P;
Fabregas, R;
Fraile, M;
Gubern, JM;
Janer, J;
... Llombart, HA; + view all
(2018)
Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials.
The Lancet Oncology
, 19
(1)
pp. 27-39.
10.1016/S1470-2045(17)30777-5.
|
 |
|
Angeles, Martina Aida;
Boria, Felix;
Shushkevich, Alexander B;
Bizzarri, Nicolo;
Theofanakis, Charalampos;
Schivardi, Gabriella;
Kacperczyk-Bartnik, Joanna;
... Ramirez, Pedro T; + view all
(2023)
Interviews conducted at the European Society of Gynaecological Oncology 2022 Congress: a ENYGO-IJGC Fellows initiative.
International Journal of Gynecological Cancer
, 33
(1)
pp. 12-18.
10.1136/ijgc-2022-004160.
|
|
Arend, RC;
Monk, BJ;
Herzog, TJ;
Moore, KN;
Shapira-Frommer, R;
Ledermann, JA;
Tewari, KS;
... Penson, RT; + view all
(2021)
Utilizing an interim futility analysis of the OVAL study (VB-111-701/GOG 3018) for potential reduction of risk: A phase III, double blind, randomized controlled trial of ofranergene obadenovec (VB-111) and weekly paclitaxel in patients with platinum resistant ovarian cancer.
Gynecologic Oncology
, 161
(2)
pp. 496-501.
10.1016/j.ygyno.2021.02.014.
|
|
Arend, Rebecca C;
Monk, Bradley J;
Shapira-Frommer, Ronnie;
Haggerty, Ashley F;
Alvarez, Edwin A;
Amit, Amnon;
Alvarez Secord, Angeles;
... OVAL/GOG-3018 Investigators; + view all
(2023)
Ofranergene Obadenovec (Ofra-Vec, VB-111) With Weekly Paclitaxel for Platinum-Resistant Ovarian Cancer: Randomized Controlled Phase III Trial (OVAL Study/GOG 3018).
Journal of Clinical Oncology
, 42
(2)
pp. 170-179.
10.1200/JCO.22.02915.
|
|
Baert, T;
Ferrero, A;
Sehouli, J;
O Donnell, DM;
González-Martín, A;
Joly, F;
Van der Velden, J;
... Ledermann, JA; + view all
(2021)
The systemic treatment of recurrent ovarian cancer revisited.
Annals of Oncology
, 32
(6)
pp. 710-725.
10.1016/j.annonc.2021.02.015.
|
|
Bangham, M;
Goldstein, R;
Walton, H;
Ledermann, JA;
(2016)
Olaparib treatment for BRCA-mutant ovarian cancer with leptomeningeal disease.
Gynecologic Oncology Reports
, 18
pp. 22-24.
10.1016/j.gore.2016.10.004.
|
|
|
Bello Roufai, Diana;
Toth, Richard;
Palo, Upasana;
Scaglione, Giula;
Palacios, Ana Tatiana;
Novak, Zoltan;
El Hajj, Houssein;
... Ledermann, Jonathan; + view all
(2025)
Tumor Board: Mechanisms of drug resistance: PARP inhibitors, antibody-drug-conjugates, and immunotherapy.
International Journal of Gynecological Cancer
, Article 102112. 10.1016/j.ijgc.2025.102112.
(In press).
|
|
Berek, JS;
Matulonis, UA;
Peen, U;
Ghatage, P;
Mahner, S;
Redondo, A;
Lesoin, A;
... Mirza, MR; + view all
(2018)
Safety and dose modification for patients receiving niraparib.
Annals of Oncology
, 29
(8)
pp. 1784-1792.
10.1093/annonc/mdy181.
|
|
Blagden, SP;
Cook, AD;
Poole, C;
Howells, L;
McNeish, IA;
Dean, A;
Kim, J-W;
... Clamp, AR; + view all
(2020)
Weekly platinum-based chemotherapy versus 3-weekly platinum-based chemotherapy for newly diagnosed ovarian cancer (ICON8): quality-of-life results of a phase 3, randomised, controlled trial.
The Lancet Oncology
, 21
(7)
pp. 969-977.
10.1016/S1470-2045(20)30218-7.
|
|
|
Boere, Ingrid;
Vergote, Ignace;
Hanssen, Rob;
Jalving, Mathilde;
Gennigens, Christine;
Ottevanger, Petronella;
van de Wouw, Yes J;
... Ledermann, Jonathan; + view all
(2023)
CINOVA: a phase II study of CPC634 (nanoparticulate docetaxel) in patients with platinum resistant recurrent ovarian cancer.
International Journal of Gynecologic Cancer
, 33
(8)
pp. 1247-1252.
10.1136/ijgc-2023-004308.
|
|
Bogani, G;
Moore, KN;
Ray-Coquard, I;
Lorusso, D;
Matulonis, UA;
Ledermann, JA;
González-Martín, A;
... Monk, BJ; + view all
(2025)
Incorporating immune checkpoint inhibitors in epithelial ovarian cancer.
Gynecologic Oncology
, 193
pp. 30-40.
10.1016/j.ygyno.2024.12.011.
|
|
Bonaca, Marc P;
Moslehi, Javid J;
Ledermann, Jonathan A;
Michelon, Elisabete;
Wei, Caimiao;
Moran, Michael;
Monk, Bradley J;
(2023)
Left Ventricular Ejection Fraction in Patients With Ovarian Cancer Treated With Avelumab, Pegylated Liposomal Doxorubicin, or Both.
The Oncologist
, 28
(10)
e977-e980.
10.1093/oncolo/oyad213.
|
 |
|
Bookman, MA;
Okamoto, A;
Stuart, G;
Yanaihara, N;
Aoki, D;
Bacon, M;
Fujiwara, K;
... Ochiai, K; + view all
(2017)
Harmonising clinical trials within the Gynecologic Cancer InterGroup: consensus and unmet needs from the Fifth Ovarian Cancer Consensus Conference.
Annals of Oncology
, 28
(S8)
viii30-viii35.
10.1093/annonc/mdx449.
|
|
Bosse, T;
Creutzberg, CL;
Crosbie, EJ;
Han, K;
Horeweg, N;
Leary, A;
Kroep, JR;
... RAINBO, Res Consortium; + view all
(2023)
Refining adjuvant treatment in endometrial cancer based on molecular features: the RAINBO clinical trial program.
International Journal of Gynecological Cancer
, 33
(1)
pp. 109-117.
10.1136/ijgc-2022-004039.
|
|
Campbell, Rachel;
Costa, Daniel SJ;
Stockler, Martin R;
Lee, Yeh Chen;
Ledermann, Jonathan A;
Berton, Dominique;
Sehouli, Jalid;
... GCIG Symptom Benefit Group; + view all
(2022)
Measure of Ovarian Symptoms and Treatment concerns (MOST) indexes and their associations with health-related quality of life in recurrent ovarian cancer.
Gynecologic Oncology
, 166
(2)
pp. 254-262.
10.1016/j.ygyno.2022.05.024.
|
|
Clamp, AR;
James, EC;
McNeish, IA;
Dean, A;
Kim, J-W;
O'Donnell, DM;
Hook, J;
... Ledermann, JA; + view all
(2019)
Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma treatment (ICON8): primary progression free survival analysis results from a GCIG phase 3 randomised controlled trial.
The Lancet
10.1016/s0140-6736(19)32259-7.
|
|
|
Clamp, AR;
Lorusso, D;
Oza, AM;
Aghajanian, C;
Oaknin, A;
Dean, A;
Colombo, N;
... Ledermann, JA; + view all
(2021)
Rucaparib maintenance treatment for recurrent ovarian carcinoma: the effects of progression-free interval and prior therapies on efficacy and safety in the randomized phase III trial ARIEL3.
International Journal of Gynecological Cancer
10.1136/ijgc-2020-002240.
(In press).
|
|
Coleman, RL;
Ledermann, JA;
(2019)
Maintenance treatment for recurrent ovarian carcinoma – Evidence supporting the efficacy and safety of PARP inhibitors.
[Review].
European Oncology and Haematology
, 15
(1)
pp. 29-40.
10.17925/EOH.2019.15.1.29.
|
|
Coleman, RL;
Oza, AM;
Lorusso, D;
Aghajanian, C;
Oaknin, A;
Dean, A;
Colombo, N;
... ARIEL3 investigators; + view all
(2017)
Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial.
The Lancet
, 390
(10106)
pp. 1949-1961.
10.1016/S0140-6736(17)32440-6.
|
|
Collinson, F;
Qian, W;
Fossati, R;
Lissoni, A;
Williams, C;
Parmar, M;
Ledermann, J;
... on behalf of the ICON1 collaborators; + view all
(2014)
Optimal treatment of early-stage ovarian cancer.
Ann Oncol
, 25
(6)
pp. 1165-1171.
10.1093/annonc/mdu116.
|
|
|
Colombo, N;
Ledermann, JA;
(2021)
Updated treatment recommendations for newly diagnosed epithelial ovarian carcinoma from the ESMO Clinical Practice Guidelines.
Annals of Oncology
, 32
(10)
pp. 1300-1303.
10.1016/j.annonc.2021.07.004.
|
|
Colombo, I;
Zaccarelli, E;
Del Grande, M;
Tomao, F;
Multinu, F;
Betella, I;
Ledermann, JA;
... Colombo, N; + view all
(2020)
ESMO management and treatment adapted recommendations in the COVID-19 era: gynaecological malignancies.
ESMO Open
, 5
, Article e000827. 10.1136/esmoopen-2020-000827.
|
|
|
Colombo, N;
Oza, AM;
Lorusso, D;
Aghajanian, C;
Oaknin, A;
Dean, A;
Weberpals, JI;
... Coleman, RL; + view all
(2020)
The effect of age on efficacy, safety and patient-centered outcomes with rucaparib: A post hoc exploratory analysis of ARIEL3, a phase 3, randomized, maintenance study in patients with recurrent ovarian carcinoma.
Gynecologic Oncology
10.1016/j.ygyno.2020.05.045.
(In press).
|
|
Colombo, N;
Sessa, C;
du Bois, A;
Ledermann, J;
McCluggage, WG;
McNeish, I;
Morice, P;
... Zeimet, AG; + view all
(2019)
ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease.
International Journal of Gynecological Cancer
, 29
(4)
pp. 728-760.
10.1136/ijgc-2019-000308.
|
|
|
Colombo, N;
Sessa, C;
du Bois, A;
Ledermann, J;
McCluggage, WG;
McNeish, I;
Morice, P;
... ESMO–ESGO Ovarian Cancer Consensus Conference Working Group, .; + view all
(2019)
ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease.
Annals of Oncology
, 30
(5)
pp. 672-705.
10.1093/annonc/mdz062.
|
|
Concin, N;
Creutzberg, CL;
Vergote, I;
Cibula, D;
Mirza, MR;
Marnitz, S;
Ledermann, JA;
... Matias-Guiu, X; + view all
(2021)
ESGO/ESTRO/ESP Guidelines for the management of patients with endometrial carcinoma.
Virchows Archiv
, 478
pp. 153-190.
10.1007/s00428-020-03007-z.
|
|
Concin, N;
Matias-Guiu, X;
Cibula, D;
Colombo, N;
Creutzberg, CL;
Ledermann, J;
Mirza, MR;
... Nout, RA; + view all
(2025)
ESGO–ESTRO–ESP guidelines for the management of patients with endometrial carcinoma: update 2025.
The Lancet Oncology
, 26
(8)
e423-e435.
10.1016/S1470-2045(25)00167-6.
|
|
Concin, N;
Matias-Guiu, X;
Vergote, I;
Cibula, D;
Mirza, MR;
Marnitz, S;
Ledermann, J;
... Creutzberg, CL; + view all
(2021)
ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma.
Radiotherapy and Oncology
, 154
pp. 327-353.
10.1016/j.radonc.2020.11.018.
|
|
Concin, N;
Matias-Guiu, X;
Vergote, I;
Cibula, D;
Mirza, MR;
Marnitz, S;
Ledermann, J;
... Creutzberg, CL; + view all
(2021)
ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma.
International Journal Of Gynecological Cancer
, 31
(1)
pp. 12-39.
10.1136/ijgc-2020-002230.
|
|
|
Coosemans, A;
Vankerckhoven, A;
Baert, T;
Boon, L;
Ruts, H;
Riva, M;
Blagden, S;
... Vergote, I; + view all
(2019)
Combining conventional therapy with immunotherapy: A risky business?
European Journal of Cancer
, 113
pp. 41-44.
10.1016/j.ejca.2019.02.014.
|
 |
|
de Boer, SM;
Powell, ME;
Mileshkin, L;
Katsaros, D;
Bessette, P;
Haie-Meder, C;
Ottevanger, PB;
... PORTEC study group, .; + view all
(2018)
Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial.
The Lancet Oncology
, 19
(3)
pp. 295-309.
10.1016/S1470-2045(18)30079-2.
|
|
de Boer, SM;
Powell, ME;
Mileshkin, L;
Katsaros, D;
Bessette, P;
Haie-Meder, C;
Ottevanger, PB;
... Creutzberg, CL; + view all
(2016)
Toxicity and quality of life after adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): an open-label, multicentre, randomised, phase 3 trial.
Lancet Oncology
, 17
(8)
pp. 1114-1126.
10.1016/S1470-2045(16)30120-6.
|
|
|
de Boer, SM;
Powell, ME;
Mileshkin, L;
Katsaros, D;
Bessette, P;
Haie-Meder, C;
Ottevanger, PB;
... Tubiana-Mathieu, N; + view all
(2019)
Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): patterns of recurrence and post-hoc survival analysis of a randomised phase 3 trial.
The Lancet Oncology
10.1016/S1470-2045(19)30395-X.
(In press).
|
|
|
Dougherty, BA;
Lai, Z;
Hodgson, DR;
Orr, MCM;
Hawryluk, M;
Sun, J;
Yelensky, R;
... Barrett, JC; + view all
(2017)
Biological and clinical evidence for somatic mutations in BRCA1 and BRCA2 as predictive markers for olaparib response in high-grade serous ovarian cancers in the maintenance setting.
Oncotarget
, 8
(27)
pp. 43653-43661.
10.18632/oncotarget.17613.
|
|
Elyashiv, O;
Ledermann, J;
Parmar, G;
Farrelly, L;
Counsell, N;
Feeney, A;
El-Khouly, F;
... Nicum, S; + view all
(2020)
ICON 9-an international phase III randomized study to evaluate the efficacy of maintenance therapy with olaparib and cediranib or olaparib alone in patients with relapsed platinum-sensitive ovarian cancer following a response to platinum-based chemotherapy.
International Journal of Gynecologic Cancer
10.1136/ijgc-2020-002073.
(In press).
|
|
|
Elyashiv, O;
Wong, YNS;
Ledermann, JA;
(2021)
Frontline Maintenance Treatment for Ovarian Cancer.
Current Oncology Reports
, 23
(8)
, Article 97. 10.1007/s11912-021-01088-w.
|
|
|
Embleton-Thirsk, A;
Deane, E;
Townsend, S;
Farrelly, L;
Popoola, B;
Parker, J;
Rustin, G;
... Kaplan, R; + view all
(2019)
Impact of retrospective data verification to prepare the ICON6 trial for use in a marketing authorization application.
Clinical Trials
, 16
(5)
pp. 502-511.
10.1177/1740774519862528.
|
|
|
Eminowicz, G;
Vaja, S;
Gallardo, D;
Kent, C;
Panades, M;
Mathew, T;
Anand, A;
... McCormack, M; + view all
(2025)
Induction chemotherapy followed by chemoradiation in locally advanced cervical cancer: Quality of life outcomes of the GCIG INTERLACE trial.
European Journal of Cancer
, 220
, Article 115375. 10.1016/j.ejca.2025.115375.
|
|
Flynn, Michael J;
Ledermann, Jonathan A;
(2022)
Ovarian cancer recurrence: is the definition of platinum resistance modified by PARPi and other intervening treatments? The evolving landscape in the management of platinum-resistant ovarian cancer.
Cancer Drug Resistance
, 5
(2)
pp. 424-435.
10.20517/cdr.2022.13.
|
|
Fotopoulou, C;
Hall, M;
Lord, R;
Miller, R;
Sundar, S;
Roebuck, N;
Fildes, L;
... Ledermann, J; + view all
(2024)
Perspectives of Healthcare Professionals on the Management and Treatment of Advanced Ovarian Cancer in the UK: Results From the KNOW-OC Survey.
Clinical Oncology
, 36
(1)
e1-e10.
10.1016/j.clon.2023.10.052.
|
|
Fotopoulou, C;
Hall, M;
Cruickshank, D;
Gabra, H;
Ganesan, R;
Hughes, C;
Kehoe, S;
... Sundar, S; + view all
(2017)
British Gynaecological Cancer Society (BGCS) epithelial ovarian/fallopian tube/primary peritoneal cancer guidelines: recommendations for practice.
European Journal of Obstetrics & Gynecology and Reproductive Biology
, 213
pp. 123-139.
10.1016/j.ejogrb.2017.04.016.
|
|
|
Francis, Katherine E;
Simon, Sandy;
Gebski, Val;
Joly, Florence;
Ledermann, Jonathan A;
Penson, Richard T;
Oza, Amit M;
... Lee, Chee Khoon; + view all
(2025)
Adverse events in the placebo arm of SOLO2/ENGOT-Ov21 maintenance trial of olaparib in recurrent ovarian cancer.
Gynecologic Oncology
, 192
pp. 50-55.
10.1016/j.ygyno.2024.11.004.
|
|
Frenel, JS;
Kim, JW;
Aryal, N;
Asher, R;
Berton, D;
Vidal, L;
Pautier, P;
... Pujade-Lauraine, E; + view all
(2022)
Efficacy of subsequent chemotherapy for patients with BRCA1/2-mutated recurrent epithelial ovarian cancer progressing on olaparib versus placebo maintenance: post-hoc analyses of the SOLO2/ENGOT Ov-21 trial.
Annals of Oncology
, 33
(10)
pp. 1021-1028.
10.1016/j.annonc.2022.06.011.
|
|
Friedlander, M;
Matulonis, U;
Gourley, C;
du Bois, A;
Vergote, I;
Rustin, G;
Scott, C;
... Ledermann, J; + view all
(2018)
Long-term efficacy, tolerability and overall survival in patients with platinum-sensitive, recurrent high-grade serous ovarian cancer treated with maintenance olaparib capsules following response to chemotherapy.
British Journal of Cancer
, 119
pp. 1075-1085.
10.1038/s41416-018-0271-y.
|
|
|
Gaillard, Thomas;
Schwameis, Richard;
Laas-Faron, Enora;
Eisenberg-Nissim, Tali;
Matias-Guiu, Xavier;
Creutzberg, Carien L;
Ledermann, Jonathan;
... Concin, Nicole; + view all
(2023)
An easy, fast, and accurate way for implementing the standards of care for the management of patients with endometrial carcinoma into daily clinical practice: the ESGO mobile app.
International Journal of Gynecological Cancer
, 33
(8)
pp. 1181-1184.
10.1136/ijgc-2023-004598.
|
|
Gilks, C Blake;
Selinger, Christina I;
Davidson, Ben;
Köbel, Martin;
Ledermann, Jonathan A;
Lim, Diana;
Malpica, Anais;
... McCluggage, W Glenn; + view all
(2022)
Data Set for the Reporting of Ovarian, Fallopian Tube and Primary Peritoneal Carcinoma: Recommendations From the International Collaboration on Cancer Reporting (ICCR).
International Journal of Gynecological Pathology
, 41
(6)
S119-S142.
10.1097/PGP.0000000000000908.
|
|
González Martín, A;
Oza, A;
Embleton, AC;
Pfisterer, J;
Ledermann, J;
Pujade-Lauraine, E;
Kristensen, G;
... Perren, T; + view all
(2019)
Exploratory outcome analyses according to stage and/or residual disease in the ICON7 trial of carboplatin and paclitaxel with or without bevacizumab for newly diagnosed ovarian cancer.
Gynecologic Oncology
, 152
(1)
10.1016/j.ygyno.2018.08.036.
|
|
|
González-Martín, A;
Harter, P;
Leary, A;
Lorusso, D;
Miller, RE;
Pothuri, B;
Ray-Coquard, I;
... ESMO Guidelines Committee; + view all
(2023)
Newly diagnosed and relapsed epithelial ovarian cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.
Annals of Oncology
, 34
(10)
pp. 833-848.
10.1016/j.annonc.2023.07.011.
|
|
Gore, M;
Hackshaw, A;
Brady, WE;
Penson, RT;
Zaino, R;
McCluggage, WG;
Ganesan, R;
... Gershenson, DM; + view all
(2019)
An international, phase III randomized trial in patients with mucinous epithelial ovarian cancer (mEOC/GOG 0241) with long-term follow-up: and experience of conducting a clinical trial in a rare gynecological tumor.
Gynecologic Oncology
, 153
(3)
pp. 541-548.
10.1016/j.ygyno.2019.03.256.
|
|
|
Gourley, C;
Miller, RE;
Hollis, RL;
Ledermann, JA;
(2020)
Role of Poly (ADP-Ribose) Polymerase inhibitors beyond BReast CAncer Gene-mutated ovarian tumours: definition of homologous recombination deficiency?
Current Opinion in Oncology
, 32
(5)
pp. 442-450.
10.1097/CCO.0000000000000660.
|
|
Gourley, C;
Balmaña, J;
Ledermann, JA;
Serra, V;
Dent, R;
Loibl, S;
Pujade-Lauraine, E;
(2019)
Moving From Poly (ADP-Ribose) Polymerase Inhibition to Targeting DNA Repair and DNA Damage Response in Cancer Therapy.
Journal of Clinical Oncology
, 37
(25)
pp. 2257-2269.
10.1200/JCO.18.02050.
|
|
Grunewald, T;
Ledermann, JA;
(2016)
Targeted Therapies for Ovarian Cancer.
Best Practice & Research Clinical Obstetrics & Gynaecology
10.1016/j.bpobgyn.2016.12.001.
(In press).
|
|
Haggstrom, Lucy;
Lee, Yeh Chen;
Scott, Clare;
Harter, Philipp;
Woelber, Linn;
Ledermann, Jonathan;
Gourley, Charlie;
... Friedlander, Michael L; + view all
(2024)
How long is long enough? An international survey exploring practice variations on the recommended duration of maintenance therapy with PARP inhibitors in patients with platinum sensitive recurrent ovarian cancer and long-term outcomes.
International Journal of Gynecological Cancer
, 34
(12)
pp. 1932-1939.
10.1136/ijgc-2024-005976.
|
|
Halaska, MJ;
Haidopoulos, D;
Guyon, F;
Morice, P;
Zapardiel, I;
Kesic, V;
Cibula, D;
... Laky, R; + view all
(2017)
European Society of Gynecological Oncology Statement on Fibroid and Uterine Morcellation.
International Journal of Gynecological Cancer
, 27
(1)
pp. 189-192.
10.1097/IGC.0000000000000911.
|
|
Hall, MR;
Dehbi, H-M;
Banerjee, S;
Lord, R;
Clamp, A;
Ledermann, JA;
Nicum, S;
... Rustin, G; + view all
(2020)
A phase II randomised, placebo-controlled trial of low dose (metronomic) cyclophosphamide and nintedanib (BIBF1120) in advanced ovarian, fallopian tube or primary peritoneal cancer.
Gynecologic Oncology
, 159
(3)
pp. 692-698.
10.1016/j.ygyno.2020.09.048.
|
|
Hall, M;
Gourley, C;
McNeish, I;
Ledermann, J;
Gore, M;
Jayson, G;
Perren, T;
... Kaye, S; + view all
(2013)
Targeted anti-vascular therapies for ovarian cancer: current evidence.
British Journal of Cancer
, 108
(2)
250 -258.
10.1038/bjc.2012.541.
|
|
|
Harter, P;
Pautier, P;
Van Nieuwenhuysen, E;
Reuss, A;
Redondo, A;
Lindemann, K;
Kurzeder, C;
... Marme, F; + view all
(2020)
Atezolizumab in combination with bevacizumab and chemotherapy versus bevacizumab and chemotherapy in recurrent ovarian cancer - a randomized phase III trial (AGO-OVAR 2.29/ENGOT-ov34).
International Journal of Gynecologic Cancer
10.1136/ijgc-2020-001572.
(In press).
|
|
|
Hodgson, DR;
Dougherty, BA;
Lai, Z;
Fielding, A;
Grinsted, L;
Spencer, S;
O'Connor, MJ;
... Barrett, JC; + view all
(2018)
Candidate biomarkers of PARP inhibitor sensitivity in ovarian cancer beyond the BRCA genes.
British Journal of Cancer
, 119
pp. 1401-1409.
10.1038/s41416-018-0274-8.
|
|
Jang, JYA;
Yanaihara, N;
Pujade-Lauraine, E;
Mikami, Y;
Oda, K;
Bookman, M;
Ledermann, J;
... Okamoto, A; + view all
(2017)
Update on rare epithelial ovarian cancers: based on the Rare Ovarian Tumors Young Investigator Conference.
Journal of Gynecologic Oncology
, 28
(4)
, Article e54. 10.3802/jgo.2017.28.e54.
|
|
Karam, A;
Ledermann, JA;
Kim, J-W;
Sehouli, J;
Lu, K;
Gourley, C;
Katsumata, N;
... Ochiai, K; + view all
(2017)
Fifth Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup: first-line interventions.
Annals of Oncology
, 28
(4)
pp. 711-717.
10.1093/annonc/mdx011.
|
|
Khoja, L;
Nolan, K;
Mekki, R;
Milani, A;
Mescallado, N;
Ashcroft, L;
Hasan, J;
... Jayson, GC; + view all
(2016)
Improved Survival from Ovarian Cancer in Patients Treated in Phase III Trial Active Cancer Centres in the UK.
Clinical Oncology
, 28
(12)
pp. 760-765.
10.1016/j.clon.2016.06.011.
|
|
|
Kristeleit, RS;
Oaknin, A;
Ray-Coquard, I;
Leary, A;
Balmaña, J;
Drew, Y;
Oza, AM;
... McNeish, IA; + view all
(2019)
Antitumor activity of the poly(ADP-ribose) polymerase inhibitor rucaparib as monotherapy in patients with platinum-sensitive, relapsed, BRCA-mutated, high-grade ovarian cancer, and an update on safety.
International Journal of Gynecological Cancer
, 29
(9)
pp. 1396-1404.
10.1136/ijgc-2019-000623.
|
|
|
Kwan, TT;
Oza, AM;
Tinker, A;
Ray-Coquard, I;
Oaknin, A;
Aghajanian, C;
Lorusso, D;
... Swisher, EM; + view all
(2021)
Preexisting TP53-Variant Clonal Hematopoiesis and Risk of Secondary Myeloid Neoplasms in Patients With High-grade Ovarian Cancer Treated With Rucaparib.
JAMA Oncology
10.1001/jamaoncol.2021.4664.
|
|
Lanceley, A;
Berzuini, C;
Burnell, M;
Gessler, S;
Morris, S;
Ryan, A;
Ledermann, JA;
(2017)
Ovarian Cancer Follow-up: A Preliminary Comparison of 2 Approaches.
International Journal of Gynecological Cancer
, 27
(1)
pp. 59-68.
10.1097/IGC.0000000000000877.
|
|
Leary, A;
Tan, D;
Ledermann, J;
(2021)
Immune checkpoint inhibitors in ovarian cancer: where do we stand?
Therapeutic Advances in Medical Oncology
, 13
10.1177/17588359211039899.
|
|
|
Ledermann, JA;
(2022)
Testing for homologous recombination deficiency – does it provide new insights for the use of veliparib?
Gynecologic Oncology
, 164
(2)
pp. 243-244.
10.1016/j.ygyno.2022.01.018.
|
|
Ledermann, JA;
Matias-Guiu, X;
Amant, F;
Concin, N;
Davidson, B;
Fotopoulou, C;
González-Martin, A;
... Fagotti, A; + view all
(2024)
ESGO–ESMO–ESP consensus conference recommendations on ovarian cancer: pathology and molecular biology and early, advanced and recurrent disease.
Annals of Oncology
, 35
(3)
pp. 248-266.
10.1016/j.annonc.2023.11.015.
|
|
Ledermann, JA;
Shapira-Frommer, R;
Santin, AD;
Lisyanskaya, AS;
Pignata, S;
Vergote, I;
Raspagliesi, F;
... Matulonis, UA; + view all
(2023)
Molecular determinants of clinical outcomes of pembrolizumab in recurrent ovarian cancer: Exploratory analysis of KEYNOTE-100.
Gynecologic Oncology
, 178
pp. 119-129.
10.1016/j.ygyno.2023.09.012.
|
|
Ledermann, JA;
Zurawski, B;
Raspagliesi, F;
De Giorgi, U;
Arranz Arija, J;
Romeo Marin, M;
Lisyanskaya, A;
... Sehouli, J; + view all
(2021)
Maintenance therapy of patients with recurrent epithelial ovarian carcinoma with the anti-tumor-associated-mucin-1 antibody gatipotuzumab: results from a double-blind, placebo-controlled, randomized, phase II study.
ESMO Open
, 7
(1)
, Article 100311. 10.1016/j.esmoop.2021.100311.
|
|
|
Ledermann, Jonathan A;
Coleman, Robert L;
(2025)
The PARP inhibitor/Immunotherapy Paradox in Advanced Ovarian Cancer: Positive Endpoints, Perplexing Interpretations.
Annals of Oncology
10.1016/j.annonc.2025.12.004.
(In press).
|
|
|
Ledermann, Jonathan A;
Oza, Amit M;
Lorusso, Domenica;
Aghajanian, Carol;
Oaknin, Ana;
Dean, Andrew;
Colombo, Nicoletta;
... Coleman, Robert L; + view all
(2025)
Rucaparib for maintenance treatment of platinum-sensitive, recurrent ovarian carcinoma: final results of the phase 3, randomized, placebo-controlled ARIEL3 trial.
European Journal of Cancer
, 225
, Article 115584. 10.1016/j.ejca.2025.115584.
|
|
Ledermann, JA;
(2019)
Do increased tumor infiltrating lymphocytes co-existing with Homologous Recombination Deficiency provide clues to enhance immunotherapy of ovarian cancer?
[Editorial comment].
Gynecologic Oncology
, 153
(2)
pp. 213-214.
10.1016/j.ygyno.2019.04.014.
|
|
Ledermann, JA;
(2019)
Extending the scope of PARP inhibitors in ovarian cancer.
[Editorial comment].
The Lancet Oncology
, 20
(4)
pp. 470-472.
10.1016/S1470-2045(19)30019-1.
|
|
Ledermann, JA;
(2018)
First-line treatment of ovarian cancer: questions and controversies to address.
Therapeutic Advances in Medical Oncology
, 10
pp. 1-8.
10.1177/1758835918768232.
|
|
Ledermann, JA;
(2017)
Front-line therapy of advanced ovarian cancer: new approaches.
Annals of Oncology
, 28
(Suppl. 8)
viii46-viii50.
10.1093/annonc/mdx452.
|
|
Ledermann, JA;
(2016)
PARP inhibitors in ovarian cancer.
Annals of Oncology
, 27
(Suppl 1)
i40-i44.
10.1093/annonc/mdw094.
|
|
Ledermann, JA;
Drew, Y;
Kristeleit, RS;
(2016)
Homologous recombination deficiency and ovarian cancer.
European Journal of Cancer
, 60
pp. 49-58.
10.1016/j.ejca.2016.03.005.
|
|
Ledermann, JA;
Embleton, AC;
Raja, F;
Perren, TJ;
Jayson, GC;
Rustin, GJS;
Kaye, SB;
... Collaborators, I; + view all
(2016)
Cediranib in patients with relapsed platinum-sensitive ovarian cancer (ICON6): a randomised, double-blind, placebo-controlled phase 3 trial.
Lancet
, 387
(10023)
pp. 1066-1074.
10.1016/S0140-6736(15)01167-8.
|
|
Ledermann, JA;
Embleton-Thirsk, AC;
Perren, TJ;
Jayson, GC;
Rustin, GJS;
Kaye, SB;
Hirte, H;
... ICON6 collaborators, .; + view all
(2021)
Cediranib in addition to chemotherapy for women with relapsed platinum-sensitive ovarian cancer (ICON6): overall survival results of a phase III randomised trial.
ESMO Open
, 6
(2)
, Article 100043. 10.1016/j.esmoop.2020.100043.
|
|
|
Ledermann, JA;
Harter, P;
Gourley, C;
Friedlander, M;
Vergote, I;
Rustin, G;
Scott, C;
... Matulonis, U; + view all
(2016)
Quality of life during olaparib maintenance therapy in platinum-sensitive relapsed serous ovarian cancer.
British Journal of Cancer
, 115
(11)
pp. 1313-1320.
10.1038/bjc.2016.348.
|
|
Ledermann, JA;
Harter, P;
Gourley, C;
Friedlander, M;
Vergote, I;
Rustin, G;
Scott, C;
... Matulonis, U; + view all
(2016)
Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial.
The Lancet Oncology
, 17
(11)
pp. 1579-1589.
10.1016/S1470-2045(16)30376-X.
|
|
Ledermann, JA;
Oza, AM;
Lorusso, D;
Aghajanian, C;
Oaknin, A;
Dean, A;
Colombo, N;
... Coleman, RL; + view all
(2020)
Rucaparib for patients with platinum-sensitive, recurrent ovarian carcinoma (ARIEL3): post-progression outcomes and updated safety results from a randomised, placebo-controlled, phase 3 trial.
Lancet Oncology
, 21
(5)
pp. 710-722.
10.1016/S1470-2045(20)30061-9.
|
|
Ledermann, JA;
Pujade-Lauraine, E;
(2019)
Olaparib as maintenance treatment for patients with platinum-sensitive relapsed ovarian cancer.
Therapeutic Advances in Medical Oncology
, 11
pp. 1-18.
10.1177/1758835919849753.
|
|
|
Lee, CK;
Friedlander, ML;
Tjokrowidjaja, A;
Ledermann, JA;
Coleman, RL;
Mirza, MR;
Matulonis, UA;
... Scott, CL; + view all
(2021)
Molecular and clinical predictors of improvement in progression-free survival with maintenance PARP inhibitor therapy in women with platinum-sensitive, recurrent ovarian cancer: A meta-analysis.
Cancer
, 127
(14)
pp. 2432-2441.
10.1002/cncr.33517.
|
|
Lee, Yeh Chen;
King, Madeleine T;
O'Connell, Rachel L;
Lanceley, Anne;
Joly, Florence;
Hilpert, Felix;
Davis, Alison;
... GCIG Symptom Benefit Group, .; + view all
(2022)
Symptom burden and quality of life with chemotherapy for recurrent ovarian cancer: the Gynecologic Cancer InterGroup-Symptom Benefit Study.
International Journal of Gynecologic Cancer
10.1136/ijgc-2021-003142.
(In press).
|
|
Lemech, CR;
Ensell, L;
Paterson, JC;
Eminowicz, G;
Lowe, H;
Arora, R;
Arkenau, H-T;
... Kristeleit, RS; + view all
(2016)
Enumeration and Molecular Characterisation of Circulating Tumour Cells in Endometrial Cancer.
Oncology
, 91
(1)
pp. 48-54.
10.1159/000445999.
|
|
Levin, Gabriel;
Harrison, Ross;
Ledermann, Jonathan;
Meyer, Raanan;
Coleman, Robert L;
Ramirez, Pedro T;
(2023)
Evaluating open access publication and research impact in gynecologic oncology.
International Journal of Gynecological Cancer
, 33
(7)
pp. 1112-1117.
10.1136/ijgc-2023-004460.
|
|
|
Lheureux, S;
Lai, Z;
Dougherty, BA;
Runswick, S;
Hodgson, DR;
Timms, KM;
Lanchbury, JS;
... Oza, AM; + view all
(2017)
Long-Term Responders on Olaparib Maintenance in High-Grade Serous Ovarian Cancer: Clinical and Molecular Characterization.
Clinical Cancer Research
, 23
(15)
pp. 4086-4094.
10.1158/1078-0432.CCR-16-2615.
|
|
Marchetti, C;
Kristeleit, R;
McCormack, M;
Mould, T;
Olaitan, A;
Widschwendter, M;
MacDonald, N;
(2017)
Outcome of patients with advanced ovarian cancer who do not undergo debulking surgery: A single institution retrospective review.
Gynecologic Oncology
, 144
(1)
pp. 57-60.
10.1016/j.ygyno.2016.11.001.
|
|
Mateo, J;
Moreno, V;
Gupta, A;
Kaye, SB;
Dean, E;
Middleton, MR;
Friedlander, M;
... Molife, LR; + view all
(2016)
An Adaptive Study to Determine the Optimal Dose of the Tablet Formulation of the PARP Inhibitor Olaparib.
Targeted Oncology
, 11
(3)
pp. 401-415.
10.1007/s11523-016-0435-8.
|
|
Matulonis, Ursula A;
Herrstedt, Jorn;
Oza, Amit;
Mahner, Sven;
Redondo, Andres;
Berton, Dominique;
Berek, Jonathan S;
... Mirza, Mansoor R; + view all
(2025)
ENGOT-OV16/NOVA trial of niraparib in recurrent ovarian cancer: Survival and long-term safety.
Gynecologic Oncology
, 195
pp. 192-199.
10.1016/j.ygyno.2025.03.018.
|
|
Matulonis, UA;
Shapira-Frommer, R;
Santin, AD;
Lisyanskaya, AS;
Pignata, S;
Vergote, I;
Raspagliesi, F;
... Ledermann, JA; + view all
(2019)
Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study.
Annals of Oncology
, 30
(7)
pp. 1080-1087.
10.1093/annonc/mdz135.
|
|
Matulonis, UA;
Walder, L;
Nøttrup, TJ;
Bessette, P;
Mahner, S;
Gil-Martin, M;
Kalbacher, E;
... Mirza, MR; + view all
(2019)
Niraparib Maintenance Treatment Improves Time Without Symptoms or Toxicity (TWiST) Versus Routine Surveillance in Recurrent Ovarian Cancer: A TWiST Analysis of the ENGOT-OV16/NOVA Trial.
Journal of Clinical Oncology
, 37
(34)
pp. 3183-3191.
10.1200/JCO.19.00917.
|
|
|
McCormack, Mary;
Eminowicz, Gemma;
Gallardo, Dolores;
Diez, Patricia;
Farrelly, Laura;
Kent, Christopher;
Hudson, Emma;
... Ledermann, Jonathan Andrew; + view all
(2024)
Induction chemotherapy followed by standard chemoradiotherapy versus standard chemoradiotherapy alone in patients with locally advanced cervical cancer (GCIG INTERLACE): an international, multicentre, randomised phase 3 trial.
The Lancet
, 404
(10462)
pp. 1525-1535.
10.1016/S0140-6736(24)01438-7.
|
|
McCormack, M;
Kadalayil, L;
Hackshaw, A;
Hall-Craggs, MA;
Symonds, RP;
Warwick, V;
Simonds, H;
... Ledermann, JA; + view all
(2013)
A phase II study of weekly neoadjuvant chemotherapy followed by radical chemoradiation for locally advanced cervical cancer.
British Journal of Cancer
, 108
(12)
2464 -2469.
10.1038/bjc.2013.230.
|
|
|
McLeavy, L;
Rahman, B;
Kristeleit, R;
Ledermann, J;
Lockley, M;
McCormack, M;
Mould, T;
... Lanceley, A; + view all
(2020)
Mainstreamed Genetic Testing in Ovarian Cancer: Patient Experience of the Testing Process.
International Journal of Gynecological Cancer
, 30
(2)
pp. 221-226.
10.1136/ijgc-2019-000630.
|
|
Merry, Eve;
Kesmez, Ronas Taner;
Yu, Tamara;
Flynn, Michael;
Ledermann, Jonathan;
Lockley, Michelle;
Macdonald, Nicola;
... Miller, Rowan; + view all
(2024)
A multicenter retrospective study to assess feasibility, safety and efficacy of first-line carboplatin-paclitaxel versus carboplatin monotherapy in a frail, elderly epithelial ovarian cancer population.
International Journal of Gynecological Cancer
10.1136/ijgc-2024-005394.
(In press).
|
|
|
Michael, Agnieszka;
Wilson, William;
Sunshine, Sunny;
Annels, Nicola;
Harrop, Richard;
Blount, Daniel;
Pandha, Hardev;
... Ledermann, Jonathan; + view all
(2024)
A randomized phase II trial to examine modified vaccinia Ankara-5T4 vaccine in patients with relapsed asymptomatic ovarian cancer (TRIOC).
International Journal of Gynecologic Cancer
10.1136/ijgc-2023-005200.
(In press).
|
|
Milani, A;
Kristeleit, R;
McCormack, M;
Raja, F;
Luvero, D;
Widschwendter, M;
MacDonald, N;
... Ledermann, JA; + view all
(2017)
Switching from standard to dose-dense chemotherapy in front-line treatment of advanced ovarian cancer: a retrospective study of feasibility and efficacy.
ESMO Open
, 1
(6)
, Article e000117. 10.1136/esmoopen-2016-000117.
|
|
Miller, RE;
Leary, A;
Scott, CL;
Serra, V;
Lord, CJ;
Bowtell, D;
Chang, DK;
... Yates, LR; + view all
(2020)
ESMO recommendations on predictive biomarker testing for homologous recombination deficiency and PARP inhibitor benefit in ovarian cancer.
Annals of Oncology
, 31
(12)
pp. 1606-1622.
10.1016/j.annonc.2020.08.2102.
|
 |
|
Miller, Rowan E;
Elyashiv, Osnat;
El-Shakankery, Karim H;
Ledermann, Jonathan A;
(2022)
Ovarian Cancer Therapy: Homologous Recombination Deficiency as a Predictive Biomarker of Response to PARP Inhibitors.
OncoTargets and Therapy
, 15
pp. 1105-1117.
10.2147/ott.s272199.
|
|
Miller, RE;
Crusz, SM;
Ledermann, JA;
(2019)
Olaparib maintenance for first-line treatment of ovarian cancer: will SOLO1 reset the standard of care?
Future Oncology
, 15
(16)
pp. 1845-1853.
10.2217/fon-2019-0057.
|
|
Miller, RE;
Ledermann, JA;
(2017)
The European Society for Medical Oncology (ESMO) Congress 2016: Highlights and summary of selected abstracts in gynecologic cancers.
Gynecologic Oncology
, 144
(1)
pp. 8-10.
10.1016/j.ygyno.2016.11.040.
|
|
Miller, RE;
Ledermann, JA;
(2016)
The status of poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitors in ovarian cancer, part 1: olaparib.
Clinical Advances in Hematology & Oncology
, 14
(8)
pp. 619-627.
|
|
|
Miller, RE;
Ledermann, JA;
(2016)
The status of poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitors in ovarian cancer, part 2: extending the scope beyond olaparib and BRCA1/2 mutations.
Clinical Advances in Hematology & Oncology
, 14
(9)
pp. 704-711.
|
|
Mirza, MR;
Benigno, B;
Dørum, A;
Mahner, S;
Bessette, P;
Barceló, IB;
Berton-Rigaud, D;
... Matulonis, UA; + view all
(2020)
Long-term safety in patients with recurrent ovarian cancer treated with niraparib versus placebo: Results from the phase III ENGOT-OV16/NOVA trial.
Gynecologic Oncology
10.1016/j.ygyno.2020.09.006.
(In press).
|
|
|
Mirza, MR;
Monk, BJ;
Herrstedt, J;
Oza, AM;
Mahner, S;
Redondo, A;
Fabbro, M;
... ENGOT-OV16/NOVA Investigators; + view all
(2016)
Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer.
The New England Journal of Medicine
, 375
(22)
pp. 2154-2164.
10.1056/NEJMoa1611310.
|
|
Mirza, MR;
Pignata, S;
Ledermann, JA;
(2018)
Latest clinical evidence and further development of PARP inhibitors in ovarian cancer.
Annals of Oncology
, 29
(6)
pp. 1366-1376.
10.1093/annonc/mdy174.
|
|
Monk, BJ;
Colombo, N;
Oza, AM;
Fujiwara, K;
Birrer, MJ;
Randall, L;
Poddubskaya, EV;
... Ledermann, JA; + view all
(2021)
Chemotherapy with or without avelumab followed by avelumab maintenance versus chemotherapy alone in patients with previously untreated epithelial ovarian cancer (JAVELIN Ovarian 100): an open-label, randomised, phase 3 trial.
The Lancet Oncology
, 22
(9)
pp. 1275-1289.
10.1016/S1470-2045(21)00342-9.
|
|
Morgan, Robert D;
Clamp, Andrew R;
Barnes, Bethany M;
Timms, Kirsten;
Schlecht, Helene;
Yarram-Smith, Laura;
Wallis, Yvonne;
... Jayson, Gordon C; + view all
(2023)
Homologous recombination deficiency in newly diagnosed FIGO stage III/IV high-grade epithelial ovarian cancer: a multi-national observational study.
International Journal of Gynecological Cancer
10.1136/ijgc-2022-004211.
(In press).
|
|
|
Morgan, RD;
McNeish, IA;
Cook, AD;
James, EC;
Lord, R;
Dark, G;
Glasspool, RM;
... Clamp, AR; + view all
(2021)
Objective responses to first-line neoadjuvant carboplatin-paclitaxel regimens for ovarian, fallopian tube, or primary peritoneal carcinoma (ICON8): post-hoc exploratory analysis of a randomised, phase 3 trial.
The Lancet Oncology
, 22
(2)
pp. 277-288.
10.1016/S1470-2045(20)30591-X.
|
|
|
Nahm, Sharon H;
Kiely, Belinda E;
O'Connell, Rachel L;
Lee, Yeh Chen;
Davis, Alison;
Avall-Lundqvist, Elisabeth;
Berek, Jonathan S;
... GCIG Symptom Benefit Group; + view all
(2025)
Prognostic significance and accuracy of oncologists' estimates of survival time in recurrent ovarian cancer.
International Journal of Gynecological Cancer
, 35
(1)
, Article 100030. 10.1016/j.ijgc.2024.100030.
|
|
Newton, C;
Murali, K;
Ahmad, A;
Hockings, H;
Graham, R;
Liberale, V;
Sarker, S-J;
... Lockley, M; + view all
(2019)
A multicentre retrospective cohort study of ovarian germ cell tumours: Evidence for chemotherapy de-escalation and alignment of paediatric and adult practice.
European Journal of Cancer
, 113
pp. 19-27.
10.1016/j.ejca.2019.03.001.
|
|
|
Newton, C;
Nordin, A;
Rolland, P;
Ind, T;
Larsen-Disney, P;
Martin-Hirsch, P;
Beaver, K;
... Fotopoulou, C; + view all
(2020)
British Gynaecological Cancer Society recommendations and guidance on patient-initiated follow-up (PIFU).
International Journal of Gynecologic Cancer
, 30
(5)
pp. 695-700.
10.1136/ijgc-2019-001176.
|
|
|
Nuttall Musson, Ellen;
Miller, Rowan E;
Mansour, Marc R;
Lockley, Michelle;
Ledermann, Jonathan A;
Payne, Elspeth M;
(2023)
Monitoring clone dynamics and reversibility in clonal haematopoiesis and myelodysplastic neoplasm associated with PARP inhibitor therapy-a role for early monitoring and intervention.
Leukemia
10.1038/s41375-023-02040-6.
(In press).
|
|
O'Malley, David M;
Oza, Amit M;
Lorusso, Domenica;
Aghajanian, Carol;
Oaknin, Ana;
Dean, Andrew;
Colombo, Nicoletta;
... Coleman, Robert L; + view all
(2022)
Clinical and molecular characteristics of ARIEL3 patients who derived exceptional benefit from rucaparib maintenance treatment for high-grade ovarian carcinoma.
Gynecologic Oncology
, 167
(3)
pp. 404-413.
10.1016/j.ygyno.2022.08.021.
|
|
Oaknin, A;
Bosse, TJ;
Creutzber, CL;
Giornelli, G;
Harter, P;
Joly, F;
Lorusso, D;
... ESMO Guidelines Committee, .; + view all
(2022)
Endometrial cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.
Annals of Oncology
, 33
(9)
pp. 860-877.
10.1016/j.annonc.2022.05.009.
|
|
Oaknin, A;
Oza, AM;
Lorusso, D;
Aghajanian, C;
Dean, A;
Colombo, N;
Weberpals, JI;
... Coleman, RL; + view all
(2021)
Maintenance treatment with rucaparib for recurrent ovarian carcinoma in ARIEL3, a randomized phase 3 trial: The effects of best response to last platinum-based regimen and disease at baseline on efficacy and safety.
Cancer Medicine
10.1002/cam4.4260.
(In press).
|
|
|
Oza, AM;
Cook, AD;
Pfisterer, J;
Embleton, A;
Ledermann, JA;
Pujade-Lauraine, E;
Kristensen, G;
... ICON7, trial investigators; + view all
(2015)
Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial.
Lancet Oncology
, 16
(8)
pp. 928-936.
10.1016/S1470-2045(15)00086-8.
|
|
|
Oza, AM;
Lorusso, D;
Aghajanian, C;
Oaknin, A;
Dean, A;
Colombo, N;
Weberpals, JI;
... Coleman, RL; + view all
(2020)
Patient-Centered Outcomes in ARIEL3, a Phase III, Randomized, Placebo-Controlled Trial of Rucaparib Maintenance Treatment in Patients With Recurrent Ovarian Carcinoma.
Journal of Clinical Oncology
10.1200/JCO.19.03107.
(In press).
|
 |
|
Pagano, Domenico;
Home, Philip;
Irs, Alar;
Ledermann, Jonathan;
Curigliano, Giuseppe;
Iwatani, Tsuguo;
Mandrola, John;
(2022)
The path for medical associations to sponsor trustworthy guidelines: is it feasible?
Journal of the Royal Society of Medicine
10.1177/01410768221095240.
(In press).
|
|
Peipert, John Devin;
Goble, Sandra;
Isaacson, Jeff;
Tang, Xiaodan;
Wallace, Katrine;
Coleman, Robert L;
Ledermann, Jonathan A;
(2023)
Patient-reported outcomes of maintenance rucaparib in patients with recurrent ovarian carcinoma in ARIEL3, a phase III, randomized, placebo-controlled trial.
Gynecologic Oncology
, 175
pp. 1-7.
10.1016/j.ygyno.2023.05060.
|
|
Post, CCB;
De Boer, SM;
Powell, ME;
Mileshkin, L;
Katsaros, D;
Bessette, P;
Haie-Meder, C;
... Creutzberg, CL; + view all
(2021)
Long-Term Toxicity and Health-Related Quality of Life After Adjuvant Chemoradiation Therapy or Radiation Therapy Alone for High-Risk Endometrial Cancer in the Randomized PORTEC-3 Trial.
International Journal of Radiation Oncology - Biology - Physics
, 109
(4)
pp. 975-986.
10.1016/j.ijrobp.2020.10.030.
|
|
Poveda, A;
Floquet, A;
Ledermann, JA;
Asher, R;
Penson, RT;
Oza, AM;
Korach, J;
... SOLO2/ENGOT-Ov21 investigators, .; + view all
(2021)
Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial.
The Lancet Oncology
, 22
(5)
pp. 620-631.
10.1016/S1470-2045(21)00073-5.
|
|
Poveda, A;
Lheureux, S;
Colombo, N;
Cibula, D;
Lindemann, K;
Weberpals, J;
Bjurberg, M;
... Škof, E; + view all
(2022)
Olaparib maintenance monotherapy in platinum-sensitive relapsed ovarian cancer patients without a germline BRCA1/BRCA2 mutation: OPINION primary analysis.
Gynecologic Oncology
10.1016/j.ygyno.2021.12.025.
(In press).
|
|
Provencher, DM;
Gallagher, CJ;
Parulekar, WR;
Ledermann, JA;
Armstrong, DK;
Brundage, M;
Gourley, C;
... MacKay, HJ; + view all
(2018)
OV21/PETROC: a randomized Gynecologic Cancer Intergroup phase II study of intraperitoneal versus intravenous chemotherapy following neoadjuvant chemotherapy and optimal debulking surgery in epithelial ovarian cancer.
Annals of Oncology
, 29
(2)
pp. 431-438.
10.1093/annonc/mdx754.
|
|
Pujade-Lauraine, E;
Fujiwara, K;
Ledermann, JA;
Oza, AM;
Kristeleit, R;
Ray-Coquard, I-L;
Richardson, GE;
... Monk, BJ; + view all
(2021)
Avelumab alone or in combination with chemotherapy versus chemotherapy alone in platinum-resistant or platinum-refractory ovarian cancer (JAVELIN Ovarian 200): an open-label, three-arm, randomised, phase 3 study.
The Lancet Oncology
, 22
(7)
pp. 1034-1046.
10.1016/S1470-2045(21)00216-3.
|
|
Pujade-Lauraine, Eric;
Fujiwara, Keiichi;
Ledermann, Jonathan A;
Oza, Amit M;
Kristeleit, Rebecca;
Ray-Coquard, Isabelle-Laure;
Richardson, Gary E;
... Monk, Bradley J; + view all
(2021)
Avelumab Alone or in Combination With Chemotherapy Versus Chemotherapy Alone in Platinum-Resistant or Platinum-Refractory Ovarian Cancer (JAVELIN Ovarian 200): An Open-Label, Three-Arm, Randomised, Phase 3 Study.
Obstetrical & Gynecological Survey
, 76
(11)
pp. 673-675.
10.1097/OGX.0000000000000980.
|
|
Pujade-Lauraine, E;
Ledermann, JA;
Selle, F;
Gebski, V;
Penson, RT;
Oza, AM;
Korach, J;
... SOLO2/ENGOT-Ov21 Investigators, .; + view all
(2017)
Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial.
The Lancet Oncology
, 18
(9)
pp. 1274-1284.
10.1016/S1470-2045(17)30469-2.
|
|
Rahman, B;
Lanceley, A;
Kristeleit, R;
Ledermann, J;
Lockley, M;
McCormack, M;
Mould, T;
(2019)
Mainstreamed genetic testing for women with ovarian cancer: first-year experience.
Journal of Medical Genetics
, 56
(3)
pp. 195-198.
10.1136/jmedgenet-2017-105140.
|
|
Ray-Coquard, Isabelle;
Ledermann, Jonathan;
DeFazio, Anna;
Okamoto, Aikou;
Gershenson, David;
(2025)
Controversies in the Organization and Structure of Management for Rare Tumors.
International Journal of Gynecological Cancer
, 35
(3)
, Article 101669. 10.1016/j.ijgc.2025.101669.
|
|
Ray-Coquard, I;
Trama, A;
Seckl, MJ;
Fotopoulou, C;
Pautier, P;
Pignata, S;
Kristensen, G;
... RARECARENet Working Group, .; + view all
(2019)
Rare ovarian tumours: Epidemiology, treatment challenges in and outside a network setting.
European Journal of Surgical Oncology
, 45
(1)
pp. 67-74.
10.1016/j.ejso.2017.09.025.
|
|
Roncalato, FT;
Berton-Rigaud, D;
O'Connell, R;
Lanceley, A;
Sehouli, J;
Buizen, L;
Okamoto, A;
... Friedlander, M; + view all
(2018)
Validation of the modified Glasgow Prognostic Score (mGPS) in recurrent ovarian cancer (ROC) – Analysis of patients enrolled in the GCIG Symptom Benefit Study (SBS).
Gynecologic Oncology
, 148
(1)
pp. 36-41.
10.1016/j.ygyno.2017.10.019.
|
|
Roncolato, Felicia;
King, Madeleine T;
O'Connell, Rachel L;
Lee, Yeh Chen;
Joly, Florence;
Hilpert, Felix;
Lanceley, Anne;
... Friedlander, Michael; + view all
(2024)
Hidden in plain sight - Survival consequences of baseline symptom burden in women with recurrent ovarian cancer.
Gynecologic Oncology
, 185
pp. 128-137.
10.1016/j.ygyno.2024.02.025.
|
|
Roncolato, FT;
O'Connell, R;
Joly, F;
Lanceley, A;
Hilpert, L;
Buizen, L;
Okamoto, E;
... Friedlander, ML; + view all
(2020)
Predictors of progression free survival, overall survival and early cessation of chemotherapy in women with potentially platinum sensitive (PPS) recurrent ovarian cancer (ROC) starting third or subsequent line(> 3) chemotherapy – the GCIG Symptom Benefit Study (SBS).
Gynecologic Oncology
, 156
(1)
pp. 45-53.
10.1016/j.ygyno.2019.10.001.
|
|
Ruers, T;
Van Coevorden, F;
Punt, CJA;
Pierie, J-PEN;
Borel-Rinkes, I;
Ledermann, JA;
Poston, G;
... and the National Cancer Research Institute Colorectal Clinical S, .; + view all
(2017)
Local Treatment of Unresectable Colorectal Liver Metastases: Results of a Randomized Phase II Trial.
JNCI: Journal of the National Cancer Institute
, 109
(9)
, Article djx015. 10.1093/jnci/djx015.
|
|
|
Sessa, C;
Balmaña, J;
Bober, SL;
Cardoso, MJ;
Colombo, N;
Curigliano, G;
Domchek, SM;
... ESMO, Guidelines Committee; + view all
(2023)
Risk reduction and screening of cancer in hereditary breast-ovarian cancer syndromes: ESMO Clinical Practice Guideline.
Annals of Oncology
, 34
(1)
pp. 33-47.
10.1016/j.annonc.2022.10.004.
|
|
Shovlin, CL;
Patel, D;
Bielowka, A;
Ledermann, JA;
Modarresi, A;
Bernabeu-Herrero, ME;
Aldred, MA;
(2023)
MEK 1 inhibition and bleeding in hereditary haemorrhagic telangiectasia.
British Journal of Haematology
10.1111/bjh.19167.
(In press).
|
|
Spanswick, VJ;
Lowe, HL;
Newton, C;
Bingham, JP;
Bagnobianchi, A;
Kiakos, K;
Craddock, C;
... Hartley, JA; + view all
(2012)
Evidence for different mechanisms of 'unhooking' for melphalan and cisplatin-induced DNA interstrand cross-links in vitro and in clinical acquired resistant tumour samples.
BMC Cancer
, 12
, Article 436. 10.1186/1471-2407-12-436.
|
|
|
Stark, D;
Cook, A;
Brown, J;
Brundage, M;
Embleton, A;
Kaplan, R;
Raja, F;
... Ledermann, J; + view all
(2017)
Quality of life with cediranib in relapsed ovarian cancer: The ICON6 phase 3 randomized clinical trial.
Cancer
, 123
(14)
pp. 2752-2761.
10.1002/cncr.30657.
|
|
Sundar, Sudha;
Nordin, Andy;
Morrison, Jo;
Wood, Nick;
Ghaem-Maghami, Sadaf;
Nieto, Jo;
Phillips, Andrew;
... Fotopoulou, Christina; + view all
(2023)
British Gynaecological Cancer Society Recommendations for Evidence Based, Population Data Derived Quality Performance Indicators for Ovarian Cancer.
Cancers
, 15
(2)
, Article 337. 10.3390/cancers15020337.
|
|
Taylor, A;
Sundar, SS;
Bowen, R;
Clayton, R;
Coleridge, S;
Fotopoulou, C;
Ghaem-Maghami, S;
... Morrison, J; + view all
(2021)
British Gynaecological Cancer Society recommendations for women with gynecological cancer who received non-standard care during the COVID-19 pandemic.
International Journal of Gynecologic Cancer
10.1136/ijgc-2021-002942.
(In press).
|
|
|
Taylor, Alexandra;
Sundar, Sudha S;
Bowen, Rebecca;
Clayton, Rick;
Coleridge, Sarah;
Fotopoulou, Christina;
Ghaem-Maghami, Sadaf;
... Morrison, Jo; + view all
(2022)
British Gynaecological Cancer Society Recommendations for Women With Gynecological Cancer Who Received Non-standard Care During the COVID-19 Pandemic.
Obstetrical and Gynecological Survey
, 77
(3)
pp. 156-157.
10.1097/01.ogx.0000822432.56370.10.
|
|
Tjokrowidjaja, A;
Friedlander, M;
Lord, SJ;
Asher, R;
Rodrigues, M;
Ledermann, JA;
Matulonis, UA;
... Lee, CK; + view all
(2021)
Prognostic nomogram for progression-free survival in patients with BRCA mutations and platinum-sensitive recurrent ovarian cancer on maintenance olaparib therapy following response to chemotherapy.
European Journal of Cancer
, 154
pp. 190-200.
10.1016/j.ejca.2021.06.024.
|
|
Tjokrowidjaja, A;
Lee, CK;
Friedlander, M;
Gebski, V;
Gladieff, L;
Ledermann, J;
Penson, R;
... Pujade-Lauraine, E; + view all
(2020)
Concordance between CA-125 and RECIST progression in patients with germline BRCA-mutated platinum-sensitive relapsed ovarian cancer treated in the SOLO2 trial with olaparib as maintenance therapy after response to chemotherapy.
European Journal of Cancer
, 139
pp. 59-67.
10.1016/j.ejca.2020.08.021.
|
|
Urkmez, E;
Andac-Jones, E;
Cibula, D;
Querleu, D;
Halaska, MJ;
Driak, D;
Sehouli, J;
... Gultekin, M; + view all
(2019)
Perceptions, expectations, and experiences of gynecological cancer patients: a pan-European ESGO-ENGAGe survey.
International Journal of Gynecological Cancer
, 29
(9)
pp. 1425-1430.
10.1136/ijgc-2019-000567.
|
|
|
Veiga, C;
Landau, D;
McClelland, JR;
Ledermann, JA;
Hawkes, D;
Janes, SM;
Devaraj, A;
(2018)
Long term radiological features of radiation-induced lung damage.
Radiotherapy and Oncology
, 126
(2)
pp. 300-306.
10.1016/j.radonc.2017.11.003.
|
|
Vergote, I;
Coens, C;
Nankivell, M;
Kristensen, GB;
Parmar, MKB;
Ehlen, T;
Jayson, GC;
... MRC CHORUS study investigators, .; + view all
(2018)
Neoadjuvant chemotherapy versus debulking surgery in advanced tubo-ovarian cancers: pooled analysis of individual patient data from the EORTC 55971 and CHORUS trials.
Lancet Oncology
, 19
(12)
pp. 1680-1687.
10.1016/S1470-2045(18)30566-7.
|
|
Willis, SE;
Winkler, C;
Roudier, MP;
Baird, T;
Marco-Casanova, P;
Jones, E;
Rowe, P;
... Jones, GN; + view all
(2021)
Retrospective analysis of Schlafen11 (SLFN11) to predict the outcomes to therapies affecting the DNA damage response.
British Journal of Cancer
10.1038/s41416-021-01560-1.
|
|
|
Wood, GE;
Ledermann, JA;
(2022)
Adjuvant and post-surgical treatment in high-grade epithelial ovarian cancer.
Best Practice & Research Clinical Obstetrics & Gynaecology
, 78
pp. 64-73.
10.1016/j.bpobgyn.2021.09.002.
|
|
Zhang, H;
AbdulJabbar, K;
Grunewald, T;
Akarca, AU;
Hagos, Y;
Sobhani, F;
Lecat, CSY;
... Yuan, Y; + view all
(2023)
Self-supervised deep learning for highly efficient spatial immunophenotyping.
eBioMedicine
, 95
, Article 104769. 10.1016/j.ebiom.2023.104769.
|
Proceedings paper
|
Haggstrom, LR;
Lee, YC;
Scott, CL;
Ledermann, JA;
Gourley, C;
McNeish, I;
Amant, F;
... Friedlander, ML; + view all
(2024)
764P How long is long enough? An international survey exploring practice variations on the recommended duration of maintenance therapy with PARP inhibitors in platinum sensitive recurrent ovarian cancer and long-term outcomes.
In: Powles, T, (ed.)
Annals of Oncology.
(pp. S578-S579).
Elsevier Ltd: Barcelona, Spain.
|
|
Zhang, H;
AbdulJabbar, K;
Grunewald, T;
Akarca, A;
Hagos, Y;
Lecat, C;
Pate, D;
... Yuan, Y; + view all
(2022)
Self-supervised Antigen Detection Artificial Intelligence (SANDI).
In: Xu, X and Li, X and Mahapatra, D and Cheng, L and Petitjean, C and Fu, H, (eds.)
Resource-Efficient Medical Image Analysis: First MICCAI Workshop, REMIA 2022, Singapore, September 22, 2022, Proceedings.
(pp. pp. 12-21).
Springer: Cham, Switzerland.
|
|
Zhang, Hanyun;
Grunewald, Tami;
Akarca, Ayse U;
Ledermann, Jonathan A;
Marafioti, Teresa;
Yuan, Yinyin;
(2021)
Symmetric Dense Inception Network for Simultaneous Cell
Detection and Classification in Multiplex Immunohistochemistry Images.
In: Atzori, Manfredo and Burlutskiy, Nikolay and Ciompi, Francesco and Li, Zhang and Minhas, Fayyaz and Müller, Henning and Peng, Tingying and Rajpoot, Nasir and Torben_Nielsen, Ben and van der Laak, Jeroen and Veta, Mitko and Yuan, Yinyin and Zlobec, Inti, (eds.)
Proceedings of the MICCAI Workshop on Computational Pathology.
(pp. pp. 246-257).
PMLR
|
Conference item
|
Miller, RE;
Devlin, M;
Brown, N;
Woo, K;
Grunewald, T;
Speirs, A;
Mitchison, M;
... Kristeleit, R; + view all
(2017)
Guidance by molecular selection improves the outcome of early phase treatment for gynecological (GYN) cancers.
Presented at: AACR Annual Meeting 2017, Washington, D.C., USA.
|
Poster
|
Miller, R;
Devlin, M-J;
Brown, NF;
Grunewald, T;
McCormack, M;
Lockley, M;
Ledermann, JA;
... Kristeleit, RS; + view all
(2017)
Outcome of patients with advanced endometrial and cervical cancer treated in a phase 1 unit.
Presented at: 2017 Annual Meeting of the American Society of Clinical Oncology (ASCO), Chicago, IL, USA.
|
|
Thesis
|
Eminowicz, GKD;
(2016)
Standardisation and optimisation of radical radiotherapy for cervical cancer.
Doctoral thesis , UCL (University College London).
|
